Europe Life Sciences Weekly Signal #43: The System Is Becoming the Product
Week of 22–28 June 2026
For a long time, life sciences companies could behave as if the product sat at the centre of everything.
Develop the asset. Generate the evidence. Secure approval. Build the launch plan. Push adoption.
That sequence still exists, of course. But it no longer explains where advantage is created.
This week’s signals point to something more uncomfortable: the system around the product is becoming as important as the product itself.
Evidence governance can now determine whether an approved product remains commercially viable. Regulatory divergence can reshape launch sequencing across major markets. AI is moving from tool adoption into leadership and operating-model design. And in MedTech, regulatory reform is no longer just a compliance topic. It is a competitiveness question.
The product still matters.
But the product is increasingly only one part of the system that determines whether science becomes adoption.
Commercial Moves
Tavneos shows why evidence governance is now a commercial capability
The sharpest signal this week came from the European Medicines Agency.
On 26 June 2026, EMA announced that its human medicines committee, the CHMP, had recommended revoking the EU marketing authorisation for Tavneos (avacopan), because its benefits were no longer proven to outweigh its risks. Tavneos is used in adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis, two rare inflammatory blood-vessel conditions.
The issue was not simply a new efficacy miss. It was the integrity of the evidence base.
EMA said the review had been initiated after new information raised questions about data integrity in the ADVOCATE study, the main study supporting the EU marketing authorisation. After reviewing the available data and how the study data had been handled, CHMP concluded that the study had been conducted in breach of good clinical practice principles. EMA said the study data submitted during the original marketing authorisation assessment were “incorrect and misleading” and could no longer be relied upon to demonstrate effectiveness.
That is the commercial signal.
This was not a conventional case of a product failing to win an expanded label. It was a marketed medicine facing removal from the EU market because the evidence foundation beneath the original approval was no longer considered reliable.
EMA also recommended that no new patients should start Tavneos and that current patients should be switched to suitable alternatives if the European Commission confirms the recommendation.
For commercial leaders, the lesson is blunt: evidence governance is no longer a regulatory back-office discipline. It is lifecycle strategy.
A medicine’s commercial position now depends not only on the original approval package, but on whether the evidence system can withstand scrutiny after approval. That system includes clinical data integrity, post-marketing evidence, safety monitoring, documentation discipline, and the ability to explain the product’s value under changing regulatory and payer expectations.
The old mental model was: evidence gets you to approval.
The newer one is: evidence keeps you in the market.
That distinction matters for launch planning, lifecycle management, medical affairs, market access, and investor confidence.
A weak evidence system is no longer just a scientific vulnerability. It is a commercial liability.
Sanofi’s tolebrutinib approval is a regulatory divergence story, not just a launch story
Sanofi had the opposite kind of regulatory week in Europe.
On 23 June 2026, Sanofi announced that the European Commission had approved Cenrifki (tolebrutinib), for the treatment of secondary progressive multiple sclerosis without relapses in the last two years. Sanofi said the approval followed a positive CHMP opinion and was based on the HERCULES phase 3 study in non-relapsing secondary progressive MS, supported by data from the GEMINI 1 and GEMINI 2 phase 3 studies in relapsing MS.
That is already commercially significant. But the more interesting story is the regulatory divergence.
In December 2025, Sanofi announced that the US FDA had issued a complete response letter for tolebrutinib in non-relapsing secondary progressive multiple sclerosis. In plain commercial terms: the US path was blocked, while the EU path has now produced approval.
That creates a different kind of launch problem.
The question is not only how to launch Cenrifki in Europe. The question is how to manage a product whose regulatory status, evidence interpretation, medical narrative, and stakeholder expectations differ across major markets.
Sanofi said it plans to make Cenrifki commercially available in Germany this year, supported by a Risk Management Program and a Patient Support Program.
That detail matters. Germany is often the first European launch market for centrally approved medicines, but approval is only the start of the operating sequence. The real work now sits across medical education, safety management, payer engagement, specialist confidence, market access sequencing, and local evidence interpretation.
For commercial teams, this is where “approval” becomes too blunt a word.
An EU approval after a US complete response letter is not just good news. It creates an operating challenge. Medical, regulatory, access, and commercial teams need to explain why Europe reached a different position, what risk controls are in place, and how the value story should be handled in each local market.
This is the kind of complexity that separates launch-ready organisations from approval-ready organisations.
AI & Digital Transformation
Sanofi hiring Paulo Fontoura from Xaira shows AI moving into the operating model
The most interesting AI signal this week was not a product announcement.
It was an executive appointment.
On 22 June 2026, Sanofi announced the appointment of Paulo Fontoura as Executive Vice President, Global Head of Research & Development Pharma, effective 1 September 2026. Sanofi said Fontoura will join the Executive Committee, be based in Paris, and report to CEO Belén Garijo.
The important detail is where he comes from.
Fontoura most recently served as Chief Medical Officer of Xaira Therapeutics, an AI-native biotechnology company focused on transforming drug discovery and development through generative artificial intelligence. Before Xaira, Fontoura spent more than 15 years at Roche, including senior global clinical development roles across neuroscience, immunology, ophthalmology, infectious disease, and rare disease.
This is not “AI leader joins biotech.”
It is the opposite.
A large pharma company is bringing in a senior R&D leader from an AI-native biotech to run R&D Pharma.
That is a more important signal than another pilot, partnership, or platform announcement.
The first phase of pharma AI was tool-centric: molecule design, target identification, trial analytics, content generation, field suggestions, and workflow automation.
The next phase is organisational.
If AI is going to affect how medicines are discovered, developed, evaluated, and launched, then it cannot sit at the edge of the company as a digital experiment. It has to become part of how decisions are made, how portfolios are prioritised, how teams are structured, and how risk is governed.
Fontoura’s appointment should be read in that context.
The question is not whether Sanofi will “use AI.” That question is already stale. The better question is what kind of R&D operating model Sanofi wants to build when AI-native thinking is no longer treated as a specialist layer outside core decision-making.
For life sciences leaders, this is the real AI transition.
Not adoption.
Integration.
And integration is always an operating-model problem before it is a technology problem.
MedTech & Market Access
MDR/IVDR reform is a competitiveness discussion, not just a compliance discussion
The MedTech signal is less dramatic than a product approval or a market withdrawal, but it may be just as consequential.
MedTech Europe’s position on the MDR/IVDR revision frames the issue clearly:
Europe’s regulatory framework for medical technologies is at a pivotal moment.
The organisation says the implementation of the Medical Devices Regulation and In Vitro Diagnostic Medical Devices Regulation has revealed structural challenges, including slow and unpredictable conformity assessment timelines, high administrative burden, and divergent interpretations across Member States.
Those problems are not administrative trivia.
MedTech Europe says they affect patient access, the availability of devices and diagnostics, and Europe’s attractiveness for investment.
That is the correct frame.
MDR and IVDR reform is often discussed as if it were mainly a regulatory workload issue: too much documentation, too many delays, too many notified-body bottlenecks.
But for investors, manufacturers, and commercial teams, predictability is not a nice-to-have. It is part of the economic model.
When regulatory pathways are slow or inconsistent, companies do not simply wait patiently. They change sequencing. They delay launches. They prioritise other regions. They narrow portfolios. They reduce European exposure. Smaller companies may struggle to fund the pathway at all.
The European Commission has proposed targeted simplification of the rules for medical devices and IVDs, aiming to make them easier, faster, and more effective while supporting competitiveness, innovation, and patient safety.
MedTech Europe supports the overall direction, especially simplification, risk-based oversight, streamlined procedures, digitalisation, and stronger international cooperation. But it also argues that targeted improvements are still needed, including clearer innovation pathways, more workable orphan and breakthrough device provisions, and clearer integration of AI requirements into MDR/IVDR conformity assessment.
For commercial leaders, this is not just a regulatory affairs story.
It affects portfolio planning, launch timing, market prioritisation, evidence strategy, pricing expectations, and investor confidence.
Europe does not only need strong science.
It needs institutions that can translate science into timely access.
Practitioner’s Lens
The common thread this week is not regulation, AI, or market access in isolation.
It is institutional capability.
Tavneos shows what happens when the evidence foundation under a marketed product no longer holds. Tolebrutinib shows how a product can be refused in one major market and approved in another, forcing launch teams to manage divergence rather than follow a simple global playbook. Fontoura’s move from Xaira to Sanofi shows AI moving from specialist experimentation toward core organisational design. MDR/IVDR reform shows that Europe’s competitiveness depends not only on innovation, but on the predictability of the system that evaluates it.
That is the strategic pattern.
Life sciences companies have spent years optimising products, channels, and functional plans.
The harder work now is coordinating the system around them.
That system includes:
– evidence governance;
– regulatory strategy;
– medical-commercial alignment;
– market access planning;
– AI governance;
– content and engagement infrastructure;
– local launch sequencing;
– post-market surveillance;
– organisational decision rights.
These used to look like supporting capabilities.
They are becoming the product’s commercial operating environment.
And in many cases, that environment determines whether the product succeeds.
The companies that outperform over the next decade will not necessarily be those with the best science alone. They will be the companies that can connect science, evidence, regulation, reimbursement, technology, and execution into one coherent operating model.
The product still opens the door.
The system decides whether anyone gets through it.
One Thing To Remember
